ADVISORY, April 29, 2011 (GLOBE NEWSWIRE) --
MELA Sciences, Inc. (MELA) will visit the NASDAQ MarketSite in New York City's Times Square in recognition of Melanoma Monday and to kick-off skin cancer awareness and detection month, as well as raise awareness about early detection of melanoma. Every hour in the U.S., one American dies of melanoma and approximately thirteen are diagnosed with melanoma.
In honor of the occasion, Dr. Elizabeth Tanzi, an internationally-known dermatologist and melanoma survivor, will ring the Closing Bell with Dr. Joseph V. Gulfo, Chief Executive Officer of MELA Sciences, Inc. (MELA). Other melanoma survivors will also be onsite to share their stories and participate in the closing bell ceremony. MELA Sciences will be sponsoring free skin cancer screenings, which will be administered by reputable board certified dermatologists onsite for NASDAQ staff and members of the media.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Monday, May 2, 2011
Free Skin Screenings 12:45 p.m. – 2:45 p.m. ET
Green Room Lunch 1:00 p.m. – 2:45 p.m.
Closing Bell 3:50 p.m. – 4:00 p.m. ET
(212) 679-3300 ext. 128
(917) 226-0816 (mobile)
The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Alexandra Honeysett (646) 441-5211.
An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About MELA Sciences, Inc. (MELA):
MELA Sciences is a medical technology company focused on developing MelaFind, a non-invasive and objective multi-spectral computer vision system intended to aid in the detection of early melanoma. MELA Sciences designed MelaFind to assist in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy to rule out melanoma. MelaFind acquires and displays multi-spectral (from blue to near infrared) and reconstructed RGB digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma, the deadliest form of skin cancer. Although no cure is currently available for advanced-stage melanoma, melanoma is virtually 100% curable if caught early.
MelaFind Proposed Indications for Use:
MelaFind® is indicated for the evaluation of clinically atypical cutaneous pigmented lesions (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 mm, evolving, patient concern, regression, and "ugly duckling"), when a dermatologist chooses to obtain additional information before making a final decision to biopsy to rule out melanoma. MelaFind® is a non-invasive and objective multi-spectral computer vision system designed as a tool to aid physicians in the detection of early (e.g., non-ulcerated, not bleeding, or less than 2.2 cm in diameter) melanoma.
MelaFind® is not a screening device and is not indicated for non-pigmented lesions, banal pigmented lesions, lesions that are clinically indentified as definite melanomas, or lesions on special anatomical sites (i.e., acral, mucosal, subungual).
The MelaFind® Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009, received positive FDA Advisory Panel recommendations in November 2010 and is currently under review at the FDA. On March 2, 2011, the Company filed an amendment to the MelaFind® pre-market approval (PMA) application with the U.S. Food and Drug Administration (FDA), limiting the indication for use to dermatologists. MELA Sciences cannot predict either the timing of the FDA's decision on the PMA application or the outcome. FDA approval is required prior to marketing MelaFind® in the United States.
For more information on MELA Sciences, visit www.melasciences.com.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with approximately 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/nasdaqomx) and Twitter (http://www.twitter.com/nasdaqomx).
Melanoma/Skin Cancer Detection and Prevention Month(R) and Melanoma Monday(R) are registered trademarks of the American Academy of Dermatology. The American Academy of Dermatology does not endorse or recommend any commercial products or services.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.